[PDF][PDF] TP53 Mutation and Survival in Chronic Lymphocytic Leukemia

…, R Busch, T Denzel, S Häbe, D Winkler… - Journal of Clinical …, 2010 - Citeseer
… Thorsten Zenz, Barbara Eichhorst, Raymonde Busch, Tina Denzel, Sonja Häbe, Dirk
Winkler, Andreas Bühler, Jennifer Edelmann, Manuela Bergmann, Georg Hopfinger …

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

…, M Ritgen, M Kneba, D Winkler… - Blood, The Journal …, 2014 - ashpublications.org
Mutations in TP53, NOTCH1, and SF3B1 were analyzed in the CLL8 study evaluating first-line
therapy with fludarabine and cyclophosphamide (FC) or FC with rituximab (FCR) among …

[HTML][HTML] Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German …

…, AM Fink, A Bühler, D Winkler… - Journal of Clinical …, 2012 - nlp.case.edu
Dirk Winkler, … Pflüger, Evangelical Diakonissenanstalt Bremen, Bremen; Andreas
Bühler, Dirk Winkler, Hartmut Döhner, and Stephan Stilgenbauer, University Hospital, Ulm; …

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow …

…, A Benner, T Denzel, D Winkler… - Blood, The Journal …, 2008 - ashpublications.org
The exact prognostic role of TP53 mutations (without 17p deletion) and any impact of the
deletion without TP53 mutation in CLL are unclear. We studied 126 well-characterized CLL …

[PDF][PDF] Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German …

…, V Goede, T Elter, A Bühler, D Winkler… - Journal of clinical …, 2011 - academia.edu
… Eckart, Gabriele Kranz, Valentin Goede, Thomas Elter, Andreas Bühler, Dirk Winkler, Michael
Kneba, Hartmut Döhner, Barbara F. Eichhorst, Michael Hallek, and Clemens-Martin Wendtner …

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL …

…, C Scheid, A Humpe, T Zenz, D Winkler… - Blood, The Journal …, 2010 - ashpublications.org
The purpose of this prospective multicenter phase 2 trial was to investigate the long-term
outcome of reduced-intensity conditioning allogeneic stem cell transplantation (alloSCT) in …

miR-34a as part of the resistance network in chronic lymphocytic leukemia

…, AP Kater, A Bühler, D Kienle, D Winkler… - Blood, The Journal …, 2009 - ashpublications.org
17p (TP53) deletion identifies patients with chronic lymphocytic leukemia (CLL) who are
resistant to chemotherapy. The members of the miR-34 family have been discovered to be direct …

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the …

S Stilgenbauer, T Zenz, D Winkler, A Buehler… - Journal of Clinical …, 2009 - ascopubs.org
Purpose The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab
in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). Clinical and …

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53 …

…, S Häbe, T Denzel, J Mohr, D Winkler… - Blood, The Journal …, 2009 - ashpublications.org
The prognosis of fludarabine (F)–refractory chronic lymphocytic leukemia (CLL) is very poor,
and underlying mechanisms are only partly understood. To assess the contribution of p53 …

Peptide arrays on cellulose support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of peptides in a parallel and addressable fashion

K Hilpert, DFH Winkler, REW Hancock - Nature protocols, 2007 - nature.com
Peptide synthesis on cellulose using SPOT technology allows the parallel synthesis of large
numbers of addressable peptides in small amounts. In addition, the cost per peptide is less …